BRPI0520438A2 - distribution of active proteins to the central nervous system using phage vectors - Google Patents

distribution of active proteins to the central nervous system using phage vectors

Info

Publication number
BRPI0520438A2
BRPI0520438A2 BRPI0520438-0A BRPI0520438A BRPI0520438A2 BR PI0520438 A2 BRPI0520438 A2 BR PI0520438A2 BR PI0520438 A BRPI0520438 A BR PI0520438A BR PI0520438 A2 BRPI0520438 A2 BR PI0520438A2
Authority
BR
Brazil
Prior art keywords
protein
nervous system
central nervous
released
phage
Prior art date
Application number
BRPI0520438-0A
Other languages
Portuguese (pt)
Inventor
Kim J Janda
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of BRPI0520438A2 publication Critical patent/BRPI0520438A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01008—Cholinesterase (3.1.1.8), i.e. butyrylcholine-esterase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

DISTRIBUIçãO DE PROTEìNAS ATIVAS PARA O SISTEMA NERVOSO CENTRAL USANDO VETORES DE FAGO. A presente invenção refere-se a um processo de distribuição de uma proteína para o sistema nervoso central em forma ativa compreende: (1) preparação de um vetor bacteriáfago filamentoso de fita simples compreendendo um constructo de ácido nucléico na qual uma proteína a ser liberada para o sistema nervoso central é codificada como uma proteína de fusão com uma proteína de revestimento de um fago filamentoso; (2) preparação de partículas de fago incorporando o constructo de ácido nucléico como o genoma de fago e onde a proteína de fusão é expressa como uma proteína de revestimento; e (3) liberando as partículas de fago para um mamífero através de uma rota de modo que as partículas de fago atinjam o sistema nervoso central de modo que a proteína seja liberada para o sistema nervoso central em forma ativa. A proteína a ser liberada pode ser um anticorpo, uma enzima, uma proteína repórter, um receptor, ou um outro tipo de proteína. O processo tem ampla aplicação terapêutica e diagnóstica. A invenção também abrange constructos de ácido nucléico, partículas de bacteriófagos incluindo a proteína a ser liberada, e composições farmacêuticas.DISTRIBUTION OF ACTIVE PROTEINS TO THE CENTRAL NERVOUS SYSTEM USING FAGUS VECTORS. The present invention relates to a process of delivering a protein to the central nervous system in active form comprising: (1) preparing a single stranded filamentous bacteriophage vector comprising a nucleic acid construct in which a protein to be released for the central nervous system is encoded as a fusion protein with a filamentous phage coat protein; (2) preparing phage particles incorporating the nucleic acid construct as the phage genome and where the fusion protein is expressed as a coat protein; and (3) releasing the phage particles to a mammal via a route so that the phage particles reach the central nervous system so that the protein is actively released to the central nervous system. The protein to be released may be an antibody, an enzyme, a reporter protein, a receptor, or another type of protein. The process has wide therapeutic and diagnostic application. The invention also encompasses nucleic acid constructs, bacteriophage particles including the protein to be released, and pharmaceutical compositions.

BRPI0520438-0A 2005-06-28 2005-06-28 distribution of active proteins to the central nervous system using phage vectors BRPI0520438A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2005/022955 WO2007001302A1 (en) 2005-06-28 2005-06-28 Delivery of active proteins to the central nervous system using phage vectors

Publications (1)

Publication Number Publication Date
BRPI0520438A2 true BRPI0520438A2 (en) 2009-05-12

Family

ID=37595417

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520438-0A BRPI0520438A2 (en) 2005-06-28 2005-06-28 distribution of active proteins to the central nervous system using phage vectors

Country Status (8)

Country Link
EP (1) EP1898701A1 (en)
JP (1) JP2009506983A (en)
AU (1) AU2005333666A1 (en)
BR (1) BRPI0520438A2 (en)
CA (1) CA2612465A1 (en)
IL (1) IL188047A0 (en)
MX (1) MX2007016286A (en)
WO (1) WO2007001302A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104800147A (en) * 2008-07-10 2015-07-29 德勒尼克斯治疗股份公司 Methods and compositions for enhanced delivery of macromolecules
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
WO2013022717A1 (en) 2011-08-05 2013-02-14 Neurophage Pharmaceuticals, Inc. Pure filamentous bacteriophage and methods of producing same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6190908B1 (en) * 1998-08-12 2001-02-20 The Scripps Research Institute Modulation of polypeptide display on modified filamentous phage
US6472147B1 (en) * 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US6686154B2 (en) * 2000-06-05 2004-02-03 Zyomyx, Inc. Screening of phage displayed peptides without clearing of the cell culture

Also Published As

Publication number Publication date
AU2005333666A1 (en) 2007-01-04
MX2007016286A (en) 2008-03-10
IL188047A0 (en) 2008-03-20
JP2009506983A (en) 2009-02-19
EP1898701A1 (en) 2008-03-19
CA2612465A1 (en) 2007-01-04
WO2007001302A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
US20200325496A1 (en) Methods and products for expressing proteins in cells
Kulkarni‐Gosavi et al. Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signalling
Jessberger The many functions of SMC proteins in chromosome dynamics
Bower et al. DRC2/CCDC65 is a central hub for assembly of the nexin–dynein regulatory complex and other regulators of ciliary and flagellar motility
BRPI0507026A (en) albumin fusion proteins
BR112016013400A2 (en) methods for modifying a genome and for producing a mouse
BR112015023168A2 (en) microcrystalline diketopiperazine compositions and methods
TNSN08064A1 (en) Albumin fusion proteins
WO2007146038A3 (en) Albumin fusion proteins
BR112015012375A2 (en) modification and regulation of crispr genome
FI3536797T3 (en) Enhanced transgene expression and processing
BR112015004848A2 (en) engineered transgene (etip) integration platform for gene targeting and feature stacking
Hamilton et al. Neuroepigenetic editing
US20190002882A1 (en) Molecular robot
Kurumizaka et al. Current progress on structural studies of nucleosomes containing histone H3 variants
CO6210831A2 (en) NEW H5 PROTEINS NUCLEIC ACID MOLECULES AND VECTORS CODING THEM AND THEIR MEDICINAL USE
BR112014032567A2 (en) iduronate-2-sulfatase purification
BR112015013997A2 (en) talcum composition
BRPI0520438A2 (en) distribution of active proteins to the central nervous system using phage vectors
Verheggen et al. CRM1 plays a nuclear role in transporting snoRNPs to nucleoli in higher eukaryotes
Gupta et al. Mapping of post-translational modifications of transition proteins, TP1 and TP2, and identification of protein arginine methyltransferase 4 and lysine methyltransferase 7 as methyltransferase for TP2
BR112016017534A2 (en) protein
Lan et al. Histone and DNA methylation control by H3 serine 10/threonine 11 phosphorylation in the mouse zygote
Tanaka Bi-orienting chromosomes: acrobatics on the mitotic spindle
Strutt et al. Adhesion GPCRs govern polarity of epithelia and cell migration

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.